ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
COVID vaccines

Japan's Takara Bio to launch contract production of mRNA vaccines

Venture's manufacturing capacity to help cut nation's reliance on imports

 Takara Bio plans to produce mRNA vaccines as early as January. (Photo courtesy of Takara Bio)

TOKYO -- Takara Bio will mass produce mRNA vaccines from next year on a contract basis, Nikkei has learned, becoming one of the first Japanese companies to build key manufacturing facilities that will help cut the nation's reliance on imports.

Takara Bio will repurpose equipment at its mainstay plant in Kusatsu, a city in Shiga Prefecture, with production starting as soon as January.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more